Search

In 1941, Dr. Huggins discovered the effectiveness of castration for prostate cancer, and this then became the main treatment for the management of prostate cancer. Although many new drugs have since been developed, they need to be used in combination with androgen deprivation therapy (ADT). In recent years, prospective randomized trials have evaluated the effectiveness of ADT combination. A comparison of 96 cases of castration-resistant prostate cancer treated with docetaxel + ADT and 102 cases treated with docetaxel alone, showed no significant difference in overall survival. Another phase II randomized trial of hormone-sensitive prostate cancer compared three treatment groups: (1) abiraterone (AAP) + ADT, (2) apalutamide (APA) alone, and (3) AAP + APA. Most patients treated with APA plus AAP (97.4%) and APA (90.0%) had a PSA decline of 80%, similar to the 100% treated with ADT plus AAP. Moreover, several studies have confirmed the clinical benefit of bipolar androgen therapy (BAT), in which the serum testosterone levels are rapidly driven to a supraphysiologic range followed by a return to near-castrate levels over a 28-day cycle. These reports suggest that continuous use of ADT may not be necessary in certain situations. Further research regarding the continuous use of ADT is warranted in the future since this therapy may not be necessary in certain situations. [ABSTRACT FROM AUTHOR]